Improving PTSD May Also Improve Diabetes Outcomes
By Lori Solomon HealthDay Reporter
THURSDAY, Aug. 15, 2024 -- No longer meeting diagnostic criteria for posttraumatic stress disorder (PTSD) is associated with a lower risk for poor diabetes outcomes, particularly among younger veterans, according to a study published online Aug. 13 in JAMA Network Open.
Jeffrey F. Scherrer, Ph.D., from the Saint Louis University School of Medicine, and colleagues examined the association between meeting diagnostic criteria for PTSD and risk for poor type 2 diabetes (T2D) outcomes among 10,002 veterans.
The researchers found that before controlling for confounding with entropy balancing, patients who no longer met PTSD diagnostic criteria had similar incidence rates for starting insulin (22.4 versus 24.4 per 1,000 person-years), poor glycemic control (137.1 versus 133.7 per 1,000 person-years), any microvascular complication (108.4 versus 104.8 per 1,000 person-years), and all-cause mortality (11.2 versus 11.0 per 1,000 person-years) compared with patients with persistent PTSD. However, when controlling for confounding, there was a lower risk for microvascular complications (hazard ratio [HR], 0.92) among those no longer meeting PTSD criteria. For younger veterans (ages 18 to 49 years), no longer meeting PTSD criteria was associated with a lower risk for insulin initiation (HR, 0.69) and all-cause mortality (HR, 0.39). No longer meeting PTSD criteria was also associated with a lower risk for insulin initiation among patients without depression (HR, 0.73).
"The findings of this study suggest that PTSD is a modifiable risk factor for some adverse T2D outcomes among patients with comorbid PTSD and T2D," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.